The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
 
Shivani Thaker
Honoraria - Doximity
 
Adam Dugan
Employment - 23andMe; Tempus AI, Inc.
Stock and Other Ownership Interests - 23andMe; Tempus
 
Unnati Jariwala
Employment - Magnit Global (Daiichi Sankyo contract assignment); Tempus AI
Stock and Other Ownership Interests - Tempus AI
 
Binyam Yilma
Employment - Tempus AI, Inc
Stock and Other Ownership Interests - Tempus AI
 
Michelle Weitz
Employment - SimBioSys; Tempus AI
Stock and Other Ownership Interests - Tempus AI
 
Stamatina Fragkogianni
Employment - Tempus
Stock and Other Ownership Interests - Tempus
 
Samer Alkassis
No Relationships to Disclose
 
Marla Lipsyc-Sharf
Honoraria - Exact Sciences; Natera; Novartis
Consulting or Advisory Role - Exact Sciences; Guardant Health; Lilly; Natera; Novartis; Stemline Therapeutics; Tersera
Speakers' Bureau - Lilly
Research Funding - Bridgebio; Natera; Stemline Therapeutics
Travel, Accommodations, Expenses - Exact Sciences; Lilly; Natera
 
Alexis LeVee
Consulting or Advisory Role - INX-315
 
Yuan Yuan
Consulting or Advisory Role - AstraZeneca; Diiachi; Genentech; Stemline Therapeutics
Speakers' Bureau - Novartis
Research Funding - Genentech; Imugene; Merck; Novartis; Pfizer
Expert Testimony - Novartis
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Biocartis; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; Go Therapeutics; GT Aperion; Guardant Health; Harbinger Health; Illumen; Incyte; Jazz Pharmaceuticals; Kivu Biosciences; Lengo Therapeutics; LigaChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Sanofi; Seagen; SystImmune; Tallac Therapeutics; Tempus; Theratechnologies; Vir Biotechnology; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); PUMA Biotechnology (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC); Physicans' Education Resource
 
Hope Rugo
Consulting or Advisory Role - BioNTech; Bristol Meyer; Helsinn Therapeutics; Napo Pharmaceuticals
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Daiichi Sankyo (Inst); F. Hoffman-La Roche/Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis
 
Mothaffar Rimawi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Novartis; Pfizer; Stemline Therapeutics; Tempus
Research Funding - Greenwich LifeSciences (Inst)
 
Rachel Schiff
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca
Research Funding - Merck; Pfizer; Puma Biotechnology; Seagen
Patents, Royalties, Other Intellectual Property - Patent pending (via institution): NRF Ref. BAYM.P0312US.P1-1001123973 “A multiparameter classifier to predict response to HER2-targeted therapy without chemotherapy in HER2-positive breast cancer” No any revenue was received.; Wolters Kluwer / UpToDate
 
David Elashoff
No Relationships to Disclose
 
Martina Mcdermott
Stock and Other Ownership Interests - 1200 Pharma; TORL Biotherapeutics
Consulting or Advisory Role - 1200 Pharma; Torl Biotherapeutics
 
Amy Cummings
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Roche; Daiichi Sankyo/Lilly; Genmab; Johnson & Johnson/Janssen; OncLive/MJH Life Sciences; Oncohost; Pfizer; Roche/Genentech; Taiho Oncology; Tempus
Research Funding - Amgen Foundation; AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for bioinformatics approach to identification of motif neoepitopes
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim
Other Relationship - California Lung Cancer Coalition
 
Jacob Mercer
Employment - Helsinn Therapeutics; QED Therapeutics; Tempus AI
Stock and Other Ownership Interests - Bridgebio
Travel, Accommodations, Expenses - Helsinn Therapeutics; Tempus AI
 
Aditya Bardia
Consulting or Advisory Role - Alyssum; Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)